Is Zoetis Inc. (ZTS) a Buy, Sell, or Hold?
NYSE : ZTS
Zoetis Inc.
$75.35 USD
$0.78 (1.05%)
- Volume
- 5.09M
- Average Volume
- 7.48M
- Market Capitalization
- $31.59B
- P/E Ratio
- 12.48
- Dividend Yield
- 2.77%
- Price Target
- $97.00
- Year High
- $160.48
- Year Low
- $71.47
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.34
- Current Ratio
- $3.15
Company Overview
NYSE
Kristin C. Peck
Drug Manufacturers - General
Healthcare
ZTS
14500
US
USD
Liquidity Metrics
2.86
3.15
1.91
0.94
0.34
Sales & Valuation
$9.47B
3.32
9.84
14.79
5.06
Profitability
$6.02
$2.67B
27.79%
34.79%
62.41%
17.44%
P/E Metrics
12.48
1.51
1.51
Analyst Price Target & Rating
$97.00
$160.00
$85.00
3/5
31 Analysts
-22.32%
Financial Health Scores
4.65
7/9
$4.42B
$15.15B
$11.92B
$3.54B
Key Metrics (TTM)
$38.89B
4.09
9.65
3.15
62.41%
21.79%
8.31%
6.76%
$32.85
326 days
Company Executives
| Name | Title |
|---|---|
| Jamie Brannan | Executive Vice President & Chief Commercial Officer |
| Kristin C. Peck | Chief Executive Officer & Director |
| Robert J. Polzer | Scientific Advisor |
| Abhay U. Nayak | Executive VP & President of U.S. Commercial Operations |
| Wetteny N. Joseph | Executive Vice President & Chief Financial Officer |
| Roxanne Lagano | Executive Vice President, General Counsel & Corporate Secretary |
| Julie A. Fuller | Executive Vice President, Chief Human Resources Officer & Global Operations |
| Keith Sarbaugh | Executive Vice President & Chief Digital and Technology Officer |
| Nick Ashton | Executive Vice President and President of Global Manufacturing & Supply |
| Steven Frank | Vice President of Investor Relations |
| Jeannette Ferran Astorga | Executive Vice President of Corporate Affairs & Chief Sustainability Officer |
Poll Results
No votes yet today — be the first to share your view!
About Zoetis Inc. (NYSE:ZTS) Stock
Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as flea ... s, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
2026-07-24 16:00:00
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit PR Newswire LOS
Zoetis Inc. (ZTS) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
2026-07-24 15:43:00
LOS ANGELES, July 24, 2026 /PRNewswire/ -- Glancy Prongay Wolke & Rotter LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Zoetis Inc. ("Zoetis" or the "Company") (NYSE: ZTS). IF YOU SUFFERED A LOSS ON YOUR ZOETIS INVESTMENTS, CLICK HERE BEFORE JULY 27, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
2026-07-24 15:32:00
Bragar Eagel & Squire, P.C. Litigation Partners Brandon Walker and Melissa Fortunato Encourage Investors Who Suffered Losses In Zoetis (ZTS) To Contact Them Directly To Discuss Their Options
2026-07-24 12:54:00
NEW YORK, July 24, 2026 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Zoetis Inc. (NYSE: ZTS).
Zoetis: Sentiment Keeps Winning As Fundamentals Improve
2026-07-24 08:00:00
Zoetis Inc. trades at a 45% discount to fair value despite resilient fundamentals and long-term growth prospects. ZTS's Q1 2026 saw 2.9% revenue growth and 8.5% adjusted EPS growth, with livestock offsetting domestic pet care weakness. Forward P/E of 10.5 is well below its 10-year average; a fair value multiple of 19 is justified given a 7.5% EPS growth consensus.
2026-07-23 23:30:00
New York, New York--(Newsfile Corp. - July 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Zoetis Inc. (NYSE: ZTS) between January 14, 2025 and May 6, 2026, inclusive (the "Class Period"), of the important July 27, 2026 lead plaintiff deadline. SO WHAT: If you purchased Zoetis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
2026-07-23 12:00:00
NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Zoetis Inc. (NYSE: ZTS) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Zoetis securities between January 14, 2025 and May 6, 2026, both dates inclusive (the “Class Period”).
2026-07-23 12:00:00
New York, New York--(Newsfile Corp. - July 23, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
Frequently Asked Questions
-
What is the current Zoetis Inc. (ZTS) stock price?
-
Zoetis Inc.(NYSE:ZTS) stock price is $75.35 in the last trading session. During the trading session, ZTS stock reached the peak price of $160.48 while $71.47 was the lowest point it dropped to. The percentage change in ZTS stock occurred in the recent session was 1.05% while the dollar amount for the price change in ZTS stock was $0.78.
-
ZTS's industry and sector of operation?
-
The NYSE listed ZTS is part of Drug Manufacturers - General industry that operates in the broader Healthcare sector.
-
Who are the executives of ZTS?
-
Jamie Brannan | Executive Vice President & Chief Commercial Officer
Kristin C. Peck | Chief Executive Officer & Director
Robert J. Polzer | Scientific Advisor
Abhay U. Nayak | Executive VP & President of U.S. Commercial Operations
Wetteny N. Joseph | Executive Vice President & Chief Financial Officer -
How many employees does ZTS have?
-
Number of ZTS employees currently stands at 14500. ZTS operates from 10 Sylvan Way, Parsippany, NJ 07054, US.
-
Link for ZTS official website?
-
Official Website of ZTS is: https://www.zoetis.com
-
How do I contact ZTS?
-
ZTS could be contacted at phone #973 822 7000 and can also be accessed through its website. ZTS operates from 10 Sylvan Way, Parsippany, NJ 07054, US.
-
How many shares of ZTS are traded daily?
-
The average number of ZTS shares traded daily for last 3 months was 7.48M.
-
What is the market cap of ZTS currently?
-
The market value of ZTS currently stands at $31.59B with its latest stock price at $75.35